Comparative effectiveness of combined antihypertensive and psychocorrective therapy in hypertensive men with anxiety and depressive disorders in the andropause period

Aim. To evaluate the effectiveness of two variants of combined antihypertensive therapy in combination with psychopharmacotherapy in hypertensive (HTN) men with anxiety and depressive disorders (ADD) in the andropause period.
Material and methods. The study involved 67 men with uncontrolled HTN and ADD in the andropause period, of whom 35 with a median age of 57 [56; 63] years took a combination of "angiotensin-converting enzyme (ACE) inhibitor perindopril + calcium channel blocker (CCB) amlodipine + antidepressant (selective serotonin reuptake inhibitor) trazodone", and 32 patients with a median age of 58,5 [57; 61] years received "angiotensin II receptor blocker (ARB) candesartan + amlodipine + trazodone". All subjects underwent 24-hour ambulatory blood pressure monitoring (ABPM) at inclusion and after 6 months of therapy, and the most significant prognostic parameters of vascular stiffness and central aortic pressure (CAP) were assessed using the BPLabVasotens hardware complex (OOO Petr Telegin, Russia).
Results. High antihypertensive and vasoprotective efficacy of both variants of combined pharmacotherapy in men with HTN and ADD in andropause was established. However, with the use of the combination of ACE inhibitor + CCB + antidepressant, more pronounced improvement of 24-hour BP profile, arterial stiffness and CAP were observed compared to patients receiving ARBs + CCB + antidepressant.
Conclusion. When comparing the antihypertensive and vasoprotective efficacy of two variants of combined pharmacotherapy in men with HTN and ADD in the andropause period, certain advantages of the combination of ACE inhibitors + CCB + antidepressant were revealed. This was manifested in a more pronounced improvement in ABPM parameters, a decrease in arterial stiffness and CAP, than in patients receiving ARB + CCB + antidepressant.

1. Moskalenko OL, Yaskevich RA. Anxiety-depressive disorders in patients with arterial hypertension (literature review). Russian Journal of Education and Psychology. 2021; (12)1-2:185-90. (In Russ.) doi: 10.12731/2658-4034-2021-12-1-2-185-190.

2. Minhas S, Patel JR, Malik M, et al. Current Problems in Cardiology. Mind-Bodi Connection: Cardiovascular Sequelae of Psychiatric Illness. 2022;47(10):100959. doi: 10.1016/j.cpcardiol.2021.100959.

3. Pogosova NV, Ausheva AK, Saner H, Boytsov SA. Stress, Anxiety and Depressive Sympoms are Predictors of Worse Outcomes in Outpatients With Arterial Hypertension and Coronary Heart Disease: Results of 1.5 Years Follow-up From the COMETA Multicenter Study. Kardiologiia. 2023;63(12):3-10. (In Russ.)

4. Shahimi NH, Lim R, Mat S, et al. Association between mental illness and blood pressure variability: a systematic review. Biomed Eng Online. 2022;21(1):19. doi: 10.1186/s12938-022-00985-w.

5. Gagulin IV, Gafarov VV, Gromova EA, et al. Gender characteristics of the risk of hypertension in the population with depression among people aged 25-64 years. Atherosclerosis. 2023;19(3):192-4. (In Russ.) doi: 10.52727/2078-256X-2023-19-3-192-194.

6. Hilliard LM, Sampson AK, Brown RD, Denton KM. The "his and hers" of the reninangiotensin system. Curr Hypertens Rep. 2013;15(1):71-9. doi: 10.1007/s11906-012-0319-y.

7. Pavlova TV, Proshchayev KI, Satardinova EE, et al. Assessment of antiety-depressive disorders and quality of life in men. Kuban Scientific Medical Bulletin. 2018;25(4):61-7. (In Russ.) doi: 10.25207/1608-6228-2018-25-4-61-67.

8. Fendrikova AV, Skibitsky VV, Skibitsky AV. Gender characteristics of vascular wall stiffness and daily blood pressure profile in patients with arterial hypertension and depression. Cardiologiia. 2020;60(12):83-9. (In Russ.) doi: 10.18087/cardio.2020.12.n1293.

9. Tikhova GP. "We are planning a clinical trial. Question No. 1: How to determine the required sample size?" Regional anesthesia and Treatment of acute pain. 2014;8(3):57-63. (In Russ.)

10. Kobalava JD, Konradi AO, Nedogoda SV, et al. Arterial hypertension in adults. Clinical Guidelines 2020. Russian Journal of Cardiology. 2020;25(3):3786. (In Russ.) doi: 10.15829/1560-4071-2020-3-3786.

11. Dedov II, Mokrysheva NG, Melnichenko GA, et al. Obesity and metabolism. Clinical recommendations "Hypogonadism syndrome in men". 2021;18(4):496-507. (In Russ.) doi: 10.14341/omet12817.

12. Wang L, Liu Q, Sun D, et al. Effects of combination treatment in hypertensive patients with depression: A systematic review and meta-analysis of 27 randomized controlled trials. Ther Clin Risk Manag. 2022;18:197-211. doi: 10.2147/TCRM.S347.

13. Mishra JS, More AS, Gopalakrishnan K, Kumar S. Testosterone plays a permissive role in angiotensin II-induced hypertension and cardiac hypertrophy in male rats. Biol Reprod. 2019;100(1):139-48. doi: 10.1093/biolre/ioy179.

14. Medina D, Mehay D, Arnold AC. Sex differences in cardiovascular actions of the reninangiotensin system. Clin Auton Res. 2020;30(5):393-408. doi: 10.1007/s10286-020-00720-2.

15. Stolov SV. Inactivation of renin-angiotensin-aldosterone system. Which class of antihypertensive medicine products to prefer? Eurasian heart journal. 2020;(4):64-78. (In Russ.) doi: 10.38109/2225-1685-2020-4-64-78.

16. Napalkov DA. Perindopril — angiotensin-converting enzyme inhibitor is approved for usage. Systemic Hypertension. 2014;11(4):75-8. (In Russ.)

17. Morozova TE, Gontarenko SV, Kuz'mina ER. Principles of choice of an angiotensinconverting enzyme inhibitor: Specific features of perindopril. Therapeutic Archive. 2014;86(9):115-8. (In Russ.)